Asunto(s)
Neoplasias del Tronco Encefálico/genética , Neoplasias del Tronco Encefálico/metabolismo , Glioma/genética , Glioma/metabolismo , Adolescente , Neoplasias del Tronco Encefálico/patología , Niño , Preescolar , Estudios de Cohortes , Metilación de ADN , Glioma/patología , Histonas/metabolismo , Humanos , Mutación , Polimorfismo de Nucleótido Simple , Proteína Fosfatasa 2C/genética , Proteína p53 Supresora de Tumor/genéticaRESUMEN
BACKGROUND AND PURPOSE: Left ventricular hypertrophy (LVH) is a maladaptive process associated with increased cardiovascular risk. Regression of LVH is associated with reduced complications of hypertension. Moxonidine is an antihypertensive imidazoline compound that reduces blood pressure primarily by central inhibition of sympathetic outflow and by direct actions on the heart to release atrial natriuretic peptide, a vasodilator and an antihypertrophic cardiac hormone. This study investigated the effect of moxonidine on LVH and the mechanisms involved in this effect. EXPERIMENTAL APPROACH: Spontaneously hypertensive rats were treated with several doses of moxonidine (s.c.) over 4 weeks. Blood pressure and heart rate were continuously monitored by telemetry. Body weight and water and food intake were measured weekly. Measurements also included left ventricular mass, DNA content, synthesis, fragmentation, and apoptotic/anti-apoptotic pathway proteins. KEY RESULTS: The decrease in mean arterial pressure stabilized at approximately -10 mm Hg after 1 week of treatment and thereafter. Compared to vehicle-treated rats (100%), left ventricular mass was dose- and time-dependently reduced by treatment. This reduction remained significantly lower after normalizing to body weight. Moxonidine reduced left ventricular DNA content and inhibited DNA synthesis. DNA fragmentation transiently, but significantly increased at 1 week of moxonidine treatment and was paralleled by elevated active caspase-3 protein. The highest dose significantly decreased the apoptotic protein Bax and all doses stimulated anti-apoptotic Bcl-2 after 4 weeks of treatment. CONCLUSIONS AND IMPLICATIONS: These studies implicate the modulation of cardiac DNA dynamics in the control of left ventricular mass by moxonidine in a rat model of hypertension.
Asunto(s)
Antihipertensivos/farmacología , ADN/efectos de los fármacos , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , Imidazoles/farmacología , Animales , Antihipertensivos/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Caspasa 3/efectos de los fármacos , Caspasa 3/metabolismo , ADN/biosíntesis , Fragmentación del ADN/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Hipertrofia Ventricular Izquierda/fisiopatología , Imidazoles/administración & dosificación , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Ratas Endogámicas SHR , Telemetría , Factores de Tiempo , Proteína X Asociada a bcl-2/efectos de los fármacos , Proteína X Asociada a bcl-2/metabolismoRESUMEN
Moxonidine, an imidazoline receptor agonist that acts centrally to inhibit sympathetic activity, has been shown to reduce effectively blood pressure, fasting insulin levels, and free fatty acids. In this study, we investigated the long-term effects of moxonidine treatment on cardiac natriuretic peptides (ANP and BNP) in Spontaneously Hypertensive Obese Rats (SHROBs), a rat model that resembles human Syndrome X. SHROBs expressing spontaneous hypertension, insulin resistance, and genetic obesity (weight 590 +/- 20 g, at 30 weeks) received moxonidine in chow at 4 mg/kg/day for 15 days. Moxonidine significantly reduced not only systolic blood pressure (187 +/- 6 versus 156 +/- 5 mm Hg, P < 0.05) but also plasma ANP (1595 +/- 371 versus 793 +/- 131 pg/mL, P < 0.05) and BNP (22 +/- 3 versus 14 +/- 1 pg/mL, P < 0.04), without influencing cardiac content of either peptide. Semi-quantitative PCR revealed that atrial ANPmRNA/GAPDHmRNA decreased to 39% 6 10% of pair-fed controls, P < 0.03. In left ventricles, moxonidine also decreased ANP mRNA to 69% +/- 7% and BNP mRNA to 74% +/- 6% of control, P < 0.02, but right ventricular ANP and BNP mRNA were not affected. These findings indicate that chronic inhibition of sympathetic activity with moxonidine in SHROB is associated with decreased ventricular natriuretic peptide transcription, consistent with the cardioprotective effects of moxonidine given the role of ANP and BNP as markers of cadiac disease. Moxonidine also improves the metabolic profile in these rats, thus it may be considered the drug of choice in treatment of metabolic syndrome X.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Imidazoles/farmacología , Obesidad/fisiopatología , Animales , Antihipertensivos/metabolismo , Antihipertensivos/farmacología , Antihipertensivos/uso terapéutico , Factor Natriurético Atrial/sangre , Factor Natriurético Atrial/genética , Presión Sanguínea/fisiología , Femenino , Atrios Cardíacos/efectos de los fármacos , Atrios Cardíacos/metabolismo , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/metabolismo , Humanos , Hipertensión/tratamiento farmacológico , Imidazoles/metabolismo , Imidazoles/uso terapéutico , Masculino , Péptido Natriurético Encefálico/sangre , Péptido Natriurético Encefálico/genética , Obesidad/tratamiento farmacológico , Ratas , Ratas Endogámicas SHRRESUMEN
The effect of treatment with moxonidine (120 mg/kg/h sc, 4 weeks) on cardiac I(1)-receptors and natriuretic peptide synthesis was evaluated in spontaneously hypertensive rats (SHR). I(1)-receptor protein (85 kD) was up-regulated in SHR atria, and normalized in right and left atria by moxonidine. Similarly, moxonidine normalized atrial and ventricular atrial natriuretic peptide messenger RNA (mRNA) and brain natriuretic peptide mRNA. This study shows that cardiac I(1)-receptors are functional, being regulated by hypertension and by chronic exposure to agonist, and that cardiac natriuretic peptides may be regulated by I(1)-receptor-mediated mechanisms.